Sec62 bridges the gap from 3q amplification to molecular cell biology in non-small cell lung cancer.

By Maximilian Linxweiler, J. Linxweiler, M. Barth, Julia Benedix, V. Jung, Yoo-Jin Kim, R. Bohle, R. Zimmermann, Markus Greiner. 2012

Subfields: Cancer Research, Cell Biology, Molecular Biology

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. M. Knebel
2. Maximilian Linxweiler
3. S. Körner
4. L. Brust
5. Matthias Schneider
6. F. Braun
7. S. Wemmert
8. J. Kühn

Citations in the corpus

• Expression of 3q Oncogene SEC62 Predicts Survival in Head and Neck Squamous Cell Carcinoma Patients Treated with Primary Chemoradiation (2023, background): “…levels were associated with unfavorable prognosis in HNSCC [22], melanoma [23], breast cancer [24], and non-small cell lung cancer (NSCLC [25,26]), advanced lymph node metastasis in NSCLC [25], melanoma [23], gastric cancer [27], colorectal cancer [28], and HNSCC [22], as well as distant…”